Related Experiment Video
Updated: Jun 8, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Daphnetin ameliorates hepatic steatosis by suppressing peroxisome proliferator-activated receptor gamma (PPARG) in
Zhen Wang1, Peipei Gao2, Jing Gao3
1Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science, Xi'an Jiaotong University, Xi'an 710049, PR China.
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is the predominant metabolic liver disorder and currently lacks effective and safe pharmaceutical interventions. Daphnetin (DA), a natural coumarin derivative with anti-inflammatory and antioxidant activities, is a promising agent for NAFLD treatment. In this study, we evaluated the effects and mechanisms of DA on hepatic lipid metabolism in ob/ob mice. Our results showed that DA effectively ameliorates glucose metabolism and hepatic lipid accumulation in ob/ob mice. Metabolomics and RNA sequencing (RNA-seq), combined with GEO data analysis, suggest that DA primarily modulates the peroxisome proliferator-activated receptor gamma (PPARG) pathway, as validated in vivo in ob/ob mice. Mechanistically, DA selectively targets PPARG in hepatic cells by inhibiting PPARG promoter activity and downregulating its expression, resulting in decreased transcription of downstream lipid metabolism-related genes, including fatty acid binding protein 4 (Fabp4), cluster of differentiation 36 (Cd36), and fatty acid synthase (Fasn). This effect was abolished in PPARG-deficient HepG2 cells subjected to palmitic acid (PA) insult. Our findings provide evidence that DA acts as a selective suppressor of hepatic PPARG, suggesting an attractive strategy by targeting PPARG for the prevention of hepatic steatosis.
Insights
Daphnetin (DA) effectively treats non-alcoholic fatty liver disease (NAFLD) by improving glucose metabolism and reducing liver fat in mice. It targets the PPARG pathway, offering a potential therapeutic strategy for hepatic steatosis.
Area of Science:
- Biochemistry
- Pharmacology
- Hepatology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder with limited pharmaceutical options.
- Daphnetin (DA), a natural coumarin, exhibits anti-inflammatory and antioxidant properties, showing promise for NAFLD treatment.
Purpose of the Study:
- To investigate the effects and mechanisms of Daphnetin (DA) on hepatic lipid metabolism in a mouse model of NAFLD.
- To elucidate DA's role in modulating the peroxisome proliferator-activated receptor gamma (PPARG) pathway.
Main Methods:
- Utilized ob/ob mice to evaluate DA's impact on glucose metabolism and hepatic lipid accumulation.
- Employed metabolomics, RNA sequencing (RNA-seq), and GEO data analysis to identify DA's molecular targets.
- Validated DA's mechanism of action in vitro using PPARG-deficient HepG2 cells.
Main Results:
- DA treatment significantly improved glucose metabolism and reduced hepatic lipid accumulation in ob/ob mice.
- DA was found to modulate the PPARG pathway, inhibiting its promoter activity and downregulating its expression.
- DA decreased the transcription of downstream lipid metabolism genes (Fabp4, Cd36, Fasn), an effect dependent on PPARG.
Conclusions:
- Daphnetin (DA) acts as a selective suppressor of hepatic PPARG, ameliorating hepatic steatosis.
- Targeting PPARG with DA presents a promising therapeutic strategy for preventing and treating non-alcoholic fatty liver disease.
